Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval

Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor